SCH 900389

SCH 900389 is an orally active, small molecule agonist of the follicle-stimulating hormone (FSH) receptor. Developed by Schering-Plough (now Merck & Co.), it was designed as a non-peptide alternative to injectable recombinant FSH (such as follitropin alfa/beta) for use in controlled ovarian stimulation during assisted reproductive technology (ART) procedures. By binding to and activating the FSH receptor on granulosa cells in the ovary, SCH 900389 stimulates follicular growth and maturation. Clinical development reached Phase 1, including studies in healthy female volunteers to assess safety, pharmacokinetics, and its effect on the pituitary-gonadal axis, often in conjunction with oral contraceptives to control the baseline hormonal environment. The program was discontinued by Merck following the acquisition of Schering-Plough.